 Receptors, Progesterone
"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
| Descriptor ID |
D011980
|
| MeSH Number(s) |
D12.776.826.750.765
|
| Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Progesterone Receptor
- Receptor, Progesterone
- Progestin Receptors
- Receptors, Progestin
- Progesterone Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 | | 1996 | 2 | 0 | 2 | | 1997 | 4 | 0 | 4 | | 1998 | 4 | 2 | 6 | | 1999 | 1 | 1 | 2 | | 2000 | 3 | 1 | 4 | | 2001 | 4 | 0 | 4 | | 2002 | 3 | 4 | 7 | | 2003 | 5 | 2 | 7 | | 2004 | 3 | 0 | 3 | | 2005 | 3 | 4 | 7 | | 2006 | 5 | 3 | 8 | | 2007 | 5 | 5 | 10 | | 2008 | 4 | 2 | 6 | | 2009 | 4 | 2 | 6 | | 2010 | 4 | 5 | 9 | | 2011 | 5 | 4 | 9 | | 2012 | 9 | 8 | 17 | | 2013 | 3 | 8 | 11 | | 2014 | 3 | 3 | 6 | | 2015 | 2 | 6 | 8 | | 2016 | 4 | 3 | 7 | | 2017 | 2 | 4 | 6 | | 2018 | 1 | 2 | 3 | | 2019 | 2 | 1 | 3 | | 2020 | 4 | 8 | 12 | | 2021 | 3 | 3 | 6 | | 2022 | 0 | 1 | 1 | | 2024 | 2 | 0 | 2 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Wesolowski R, Rugo HS, Specht JM, Han HS, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin Cancer Res. 2025 Oct 01; 31(19):4040-4048.
-
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA. Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial. J Clin Oncol. 2025 Aug 20; 43(24):2712-2719.
-
Joshi S, Williamson J, Baca SM, Kapur J. Progesterone receptors regulate susceptibility to spreading depression. Exp Neurol. 2025 Mar; 385:115139.
-
Brechbuhl HM, Sartorius CA. Sticky Business: Progesterone Receptors Mediate Cancer Associated Fibroblast and Breast Cancer Cell Interaction. Endocrinology. 2024 Aug 27; 165(10).
-
John EM, Koo J, Phipps AI, Longacre TA, Kurian AW, Ingles SA, Wu AH, Hines LM. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study. Breast Cancer Res. 2024 05 31; 26(1):88.
-
Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci Transl Med. 2022 Sep 21; 14(663):eabo5959.
-
Borges VF. Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When? J Clin Oncol. 2021 12 10; 39(35):3890-3896.
-
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022 02; 126(2):302-309.
-
Cole SE, John EM, Hines LM, Phipps AI, Koo J, Ingles SA, Baumgartner KB, Slattery ML, McKean-Cowden R, Wu AH. Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities Study. Int J Cancer. 2022 01 15; 150(2):208-220.
-
Lorona NC, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes Control. 2021 Dec; 32(12):1375-1384.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|